8-K: Corvus Pharmaceuticals Reports Positive Clinical Trial Updates and Secures $30.6 Million in Financing

Corvus Pharmaceuticals announced encouraging clinical trial results for its drug candidates and a successful $30.6 million financing round.

Summary

• Corvus Pharmaceuticals provided a business update and reported its first quarter 2024 financial results.
• The company is advancing soquelitinib for Peripheral T-Cell Lymphoma (PTCL) and generating early data for soquelitinib in atopic dermatitis.
• Two new PTCL patients in the Phase 1 trial achieved objective responses, including one complete response and one partial response.
• A Phase 3 registration trial for soquelitinib in PTCL is on track to begin in the third quarter of 2024.
• The company closed a registered direct offering on May 6, 2024, raising approximately $30.6 million.
• Interim data from the ciforadenant Phase 1b/2 trial in renal cell cancer exceeded the predefined deep response threshold.
• Corvus expects its cash to fund operations into the fourth quarter of 2025.
• The company anticipates early interim data from the Phase 1 trial of soquelitinib in atopic dermatitis by year-end 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with encouraging clinical trial results and a successful capital raise. The company is making progress on its key programs and has secured funding to continue operations into late 2025. There are some risks, but the overall tone is optimistic.

Positives

• The company has made strong progress with its two key priorities for the year.
• The recent financing provides runway through several expected clinical readouts in 2024 and 2025.
• The initial clinical results from the ciforadenant Phase 1b/2 trial are encouraging.
• The company has identified a novel mechanism leveraging the combination of adenosine antagonism and checkpoint inhibitors.
• The company has a 49.7% equity stake in Angel Pharmaceuticals.
• Research and development expenses decreased by $0.5 million compared to the same period in 2023.

Negatives

• The company had a net loss of $5.7 million for the three months ended March 31, 2024.
• Cash, cash equivalents, and marketable securities decreased from $27.1 million at the end of 2023 to $22.1 million as of March 31, 2024.

Risks

• The company's ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials is not guaranteed.
• The results of preclinical studies and interim data from clinical trials may not be predictive of future results.
• The company's ability to enroll sufficient numbers of patients in its clinical trials is a risk.
• The regulatory process is unpredictable.
• The costs of clinical trials may exceed expectations.
• The company's ability to raise additional capital is a risk.

Future Outlook

Corvus expects its cash to fund operations into the fourth quarter of 2025 and anticipates several clinical readouts in 2024 and 2025, including early data for soquelitinib in atopic dermatitis by the end of 2024, and final data in 2025, initial Phase 1 data in solid tumors in the second half of 2025, and additional ciforadenant data later this year.

Management Comments

• Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus, stated that they continue to make strong progress with their two key priorities for the year.
• Dr. Miller also mentioned that they are encouraged by the initial clinical results from their Phase 1b/2 trial of ciforadenant.
• Kathryn Beckermann, M.D., PhD, lead investigator of the ciforadenant Phase 1b/2 clinical trial, stated that ciforadenant adds a new immunotherapeutic mechanism that may be synergistic to the standard regimen.

Industry Context

This announcement is relevant to the biopharmaceutical industry, particularly companies focused on developing novel immunotherapies for cancer and autoimmune diseases. The progress of soquelitinib in PTCL and atopic dermatitis, as well as ciforadenant in renal cell cancer, positions Corvus as a player in the competitive landscape of targeted therapies.

Comparison to Industry Standards

• The 39% objective response rate (ORR) with soquelitinib in relapsed PTCL is promising compared to the poor outcomes typically seen with chemotherapy in this setting, where median progression-free survival is in the three to four month range and overall median survival is six to 12 months.
• The deep response rate achieved with ciforadenant in combination with ipilimumab and nivolumab exceeds the 32% rate seen in previous trials with ipilimumab/nivolumab alone, suggesting a potential improvement in efficacy.
• The company's focus on ITK inhibition and adenosine antagonism aligns with current trends in immunotherapy research, which seeks to overcome resistance mechanisms and enhance anti-tumor responses.
• Companies like Kite Pharma and Juno Therapeutics are also developing cell therapies for lymphomas, while companies like Bristol Myers Squibb and Merck are developing checkpoint inhibitors for various cancers. Corvus is differentiating itself with its focus on ITK inhibition and adenosine antagonism.

Related Party Transactions

• Sublease income from a related party was $0 for the three months ended March 31, 2024, compared to $56,000 for the same period in 2023.

Stakeholder Impact

• Shareholders will be impacted by the positive clinical trial results and the successful capital raise.
• Employees will be impacted by the continued funding of operations and the advancement of the company's programs.
• Patients with PTCL, atopic dermatitis, and renal cell cancer may benefit from the development of new therapies.
• The company's collaboration with Angel Pharmaceuticals may impact stakeholders in China.

Next Steps

• Initiate a registrational Phase 3 clinical trial of soquelitinib in patients with relapsed PTCL in the third quarter of 2024.
• Continue enrollment in the Phase 1 trial of soquelitinib in atopic dermatitis.
• Advance next-generation ITK inhibitor preclinical product candidates.
• Continue collaboration with Kidney Cancer Research Consortium on the ciforadenant trial.
• Monitor the progress of the mupadolimab trial being conducted by Angel Pharmaceuticals.

Key Dates

Keywords

Soquelitinib, Ciforadenant, Mupadolimab, PTCL, Atopic Dermatitis, Renal Cell Cancer, Immunotherapy, Clinical Trial, ITK Inhibitor, Adenosine Antagonist, Checkpoint Inhibitor, Biopharmaceutical